London-based GSK has introduced two cancer medicines Jemperli for certain advanced endometrial cancers and Zejula for advanced ovarian cancer, marking its formal entry into India’s oncology market. These cancers are increasingly common among Indian women, and many patients are diagnosed at later stages where treatment choices are limited. Endometrial and...
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech
GSK has announced a licensing agreement with Hyderabad, India-based Bharat Biotech for its Shigella vaccine candidate, altSonflex 1-2-3. This collaboration signifies a step in addressing the global burden of Shigella, a bacterial infection that causes severe diarrhea and is responsible for thousands of deaths annually, predominantly among children under five....
India Gets Recognition as a Global Clinical Trials Hub
India is rapidly emerging as a premier global destination for multinational pharmaceutical companies to conduct clinical trials. This marks a significant shift in the industry landscape, driven by India's simplified, accessible, and expedited clinical trial processes. Over the past decade, India has experienced substantial growth of 15-18% in Phase 2...
In 2018 M&As Lead $100-Bn Plus Deals in India
2018 proved to be a robust year for mergers and acquisitions for Indian corporations. Powered by the Insolvency and Bankruptcy Code and an extremely competitive atmosphere in the mobile and e-commerce space, dealmaking crossed $100 billion for the first time ever. As the government pushed for resolutions, there was a...
GSK Partners with India's Syngene for R&D
U.K.-based pharmaceutical company GlaxoSmithKline, popularly known as GSK, signed an R&D agreement with Syngene International, a global contract research services company based in Bangalore, India. The multi-year agreement will focus on accelerating the discovery of new drug candidates with the potential to address some of the world’s most pressing healthcare needs....
India's Pharma Industry Becoming Increasingly Digital
The Economic Times reports that in a survey of drug making companies in India's $17 billion pharmaceutical industry the top 20 of them are changing their conservative ways of marketing for newer technology ranging from scientific detailing to doctors to using newer algorithms for better insights into issues like patient...